{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:34Z","timestamp":1786944274512,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chromosome 1q abnormalities are among the most frequent cytogenetic alterations in multiple myeloma (MM), yet their prognostic relevance has been reported inconsistently and varies across current risk stratification models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective single-center study to evaluate the clinical impact of 1q abnormalities in 140 patients with newly diagnosed MM undergoing autologous stem cell transplantation (ASCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fluorescence\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridization at diagnosis identified 1q alterations in 40% of patients, including 1q gain (3 copies; 29.3%) and amplification (\u22654 copies; 10.7%). Patients with 1q amplification had significantly shorter progression-free survival (PFS) compared to those without 1q abnormalities, whereas 1q gain was not associated with inferior outcomes. Notably, patients with co-occurring high-risk cytogenetic features (\u201cdouble-hit\u201d) had the poorest outcomes, while isolated 1q alterations did not independently impact survival. Despite achieving deeper responses both prior to and at day 100 after ASCT, patients with 1q gain\/amplification did not experience improved long-term outcomes, underscoring the limited prognostic value of response assessment at a single time point. In multivariable analyses, established risk factors, including ISS stage III and IMWG high-risk cytogenetics, remained independently associated with PFS and overall survival (OS), whereas 1q abnormalities did not, although the limited number of patients with 1q amplification warrants cautious interpretation. Maintenance therapy was associated with improved PFS but not OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, the prognostic relevance of chromosome 1q alterations in transplant-eligible newly diagnosed MM appears to be primarily driven by copy number burden and co-occurrence with other high-risk lesions rather than by their isolated presence. These findings support the integration of 1q abnormalities into composite risk models to improve risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1896152","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:33:19Z","timestamp":1786941199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chromosome 1q alterations in transplant-eligible multiple myeloma: clinical impact of copy number and co-occurring high-risk cytogenetic features"],"prefix":"10.3389","volume":"16","author":[{"given":"Irene","family":"Strassl","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bindeus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Burghofer","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Genetics Diagnostics, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Erdel","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Genetics Diagnostics, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Machherndl-Spandl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Saini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Wipplinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Kaynak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Milanov","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rotter","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hasengruber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Mair","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nikoloudis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Weltermann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Clausen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz","place":["Linz, Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02228","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meeting"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/978-1-59259-817-5_8","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-173697","article-title":"Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: The MD Anderson Cancer Center experience","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","volume":"43","author":"Kaiser","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(25)03690-0","article-title":"Development of a cytogenetic double-hit model for survival prediction in multiple myeloma","volume":"17","author":"Du","year":"2025","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-018-0436-7","article-title":"Educational no. 3: Cytogenetic analysis (CA)","volume":"11","author":"Erdel","year":"2018","journal-title":"Memo - Magazine Eur Med Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"Jco2101935","DOI":"10.1200\/jco.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): Final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70198","article-title":"Prognostic impact of chromosome 1q gain\/amplification in multiple myeloma treated with daratumumab-based regimens","volume":"117","author":"Barbieri","year":"2026","journal-title":"Eur J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00277-026-07072-3","article-title":"Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: A monocentric study","volume":"105","author":"Iannozzi","year":"2026","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:33:32Z","timestamp":1786941212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1896152"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1896152","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1896152"}}